ResultsIQ

ResultsIQ › Latest results › Healthcare Global Enterprises Limited

Healthcare Global Enterprises Limited Q4 FY26 results deck summary

NSE: HCG · BSE: 539787

Results deck of 19 May 2026, summarised by AI from the filing.

Revenue ₹6,523.3 mn (+11% YoY) and adjusted EBITDA ₹1,252.3 mn (+17% YoY) with margin at 19.2%.

Key takeaways

  1. Q4 FY26 Revenue ₹6,523.3 mn (+11% YoY) and adjusted EBITDA ₹1,252.3 mn (+17% YoY) with margin at 19.2%.
  2. Milann exit HCG agreed to divest 100% of Milann at ₹632 mn enterprise valuation, expected to close in Q1 FY27.
  3. Growth driver West cluster grew ~13% YoY in Q4 FY26 on patient inflows across Gujarat and Maharashtra.
  4. Risk ARPP moderated in East due to clinical transitions in Kolkata impacting case mix.

Original filing on BSE

Healthcare Global Enterprises Limited Q1 FY27 results

As filed: Revenue ₹695 cr (+13% year on year), EBITDA ₹122 cr (+14% year on year), PAT ₹16.5 cr (+174% year on year), EBITDA margin 17.6% (+13 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹652 cr (+12% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹4.0 cr (+133% year on year), EBITDA margin 19.2% (+105 bps). Score 48 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was well above it. EBITDA margin rose 105 bps year on year. Other income 1790% of PBT. Tax rate -382%. Revenue rose ₹67.3 cr on a year ago, against ₹90.0 cr the year before. Share price after the results: −5.0% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹633 cr (+13% year on year), EBITDA ₹110 cr (+25% year on year), PAT −₹7.9 cr, EBITDA margin 17.3% (+154 bps). Score 65 of 100, Above trend. Revenue growth was below the company's own trend; EBITDA growth was well above it. EBITDA margin rose 154 bps year on year. Profit fell 67% from last quarter. Revenue rose ₹75.1 cr on a year ago, against ₹88.0 cr the year before. Share price after the results: −1.8% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹647 cr (+17% year on year), EBITDA ₹124 cr (+20% year on year), PAT ₹21.0 cr (0% year on year), EBITDA margin 19.2% (+57 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was below it. EBITDA margin rose 57 bps year on year. Tax rate -5%. Consolidated profit +0% but standalone -31%. Revenue rose ₹93.0 cr on a year ago, more than the ₹67.0 cr it added the year before. Share price after the results: −4.4% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹613 cr (+17% year on year), EBITDA ₹107 cr (+18% year on year), PAT ₹6.0 cr (−57% year on year), EBITDA margin 17.5% (+15 bps). Score 38 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 15 bps year on year. Other income 64% of PBT. Tax rate 55%. Profit fell 14% from last quarter. Revenue rose ₹87.0 cr on a year ago, more than the ₹65.0 cr it added the year before. Share price after the results: +12.2% in 29 days (Nifty 500: −4.7%).
  • Q4 FY25: Revenue ₹585 cr (+18% year on year), EBITDA ₹106 cr (+15% year on year), PAT ₹7.0 cr (−70% year on year), EBITDA margin 18.1% (−47 bps). Score 37 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin fell 47 bps year on year. Other income 71% of PBT. Tax rate 50%. Profit fell 13% from last quarter. Revenue rose ₹90.0 cr on a year ago, more than the ₹53.0 cr it added the year before. Share price after the results: −11.1% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹558 cr (+19% year on year), EBITDA ₹88.0 cr (+13% year on year), PAT ₹8.0 cr (+167% year on year), EBITDA margin 15.8% (−83 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 83 bps year on year. Consolidated profit +167% but standalone -562%. Profit fell 62% from last quarter. Revenue rose ₹88.0 cr on a year ago, more than the ₹45.0 cr it added the year before.
  • Q2 FY25: Revenue ₹554 cr (+14% year on year), EBITDA ₹103 cr (+21% year on year), PAT ₹21.0 cr (+91% year on year), EBITDA margin 18.6% (+114 bps). Score 64 of 100, In line with trend. EBITDA margin rose 114 bps year on year. Other income 39% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Healthcare Global Enterprises Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.